Table 1.

Characteristics and treatments of patients according to EPIC version administered. Distribution of the EPIC domains’ scores at 12 months after treatment

	Patients with EPIC-26 (n = 534)	Patients with EPIC-50 (n = 324)	p value*
Characteristics
Age at recruitment, years, mean (SD)	68.1 (8.0)	67.9 (8.0)	0.652
Tumoral stage, n (%)
Tx	8 (1.5%)	1 (0.3%)	0.346
T0	1 (0.2%)	1 (0.3%)
T1	250 (46.0%)	162 (50.2%)
T2	184 (33.9%)	102 (31.6%)
T3	97 (17.9%)	57 (17.6%)
T4	3 (0.6%)	0 (0.0%)
PSA, mean (SD)	11.1 (13.8)	9.4 (9.0)	0.049
Gleason score, mean (SD)	7.1 (0.9)	6.8 (1.0)	< 0.001
D’Amico tumoral risk, n (%)
Low	94 (17.4%)	102 (31.6%)	< 0.001
Intermediate	249 (46.1%)	128 (39.6%)
High	197 (36.5%)	93 (28.8%)
Initial primary treatment
External radiotherapy, n (%)	282 (51.9%)	181 (55.9%)	< 0.001
Radical prostatectomy, n (%)	185 (34.1%)	83 (25.6%)
Brachytherapy as monotherapy, n (%)	38 (7.0%)	44 (13.6%)
Active surveillance, n (%)	29 (5.3%)	3 (0.9%)
Focal brachytherapy, n (%)	9 (1.7%)	13 (4.0%)
Distribution of the EPIC scores
Urinary incontinence
Observed range	0–100	0–100
Floor and ceiling effect (%)	0.9%; 54.1%	1.9%; 62.7%
Mean (SD)	77.9 (28.2)	81.5 (27.5)
Cronbach’s alpha	0.90	0.91
Urinary irritative/obstructive
Observed range	0–100	7.1–100
Floor and ceiling effect (%)	0.7%; 42.5%	0.0%; 36.4%
Mean (SD)	80.6 (22.5)	84.5 (17.7)
Cronbach’s alpha	0.67	0.63
Bowel
Observed range	0–100	28.6–100
Floor and ceiling effect (%)	0.4%; 66.1%	0.0%; 61.7%
Mean (SD)	88.1 (21.2)	92.0 (14.1)
Cronbach’s alpha	0.84	0.87
Sexual
Observed range	0–87.5	0–90.4
Floor and ceiling effect (%)	1.8%; 0.0%	0.3%; 0.0%
Mean (SD)	34.8 (27.4)	43.6 (19.9)
Cronbach’s alpha	0.86	0.88
Hormonal
Observed range	0–100	4.6–100
Floor and ceiling effect (%)	1.3%; 38.9%	0.0%; 29.9%
Mean (SD)	74.2 (28.0)	82.2 (19.7)
Cronbach’s alpha	0.78	0.84

*p-values were estimated with Chi-square test or unpaired Student’s t test